Despite a slower start to the year, the fundamental drivers for M&A remain strong. Barclays' M&A head notes that pharmaceutical companies face near-term patent expirations and have ample capital, ensuring that dealmaking will persist in cycles rather than structurally decline.
An improving IPO market doesn't cannibalize M&A activity but rather provides private companies with a dual-track option. Barclays advises clients to evaluate both public market and M&A paths simultaneously, treating them as complementary strategies for value creation, not mutually exclusive choices.
Contrary to seeking fully de-risked assets, pharmaceutical companies often prefer acquiring companies with some remaining clinical risk. This strategy allows them to leverage unique insights on early data to acquire assets at a better valuation, creating an opportunity for outsized returns before the value is obvious to others.